FIELD: chemistry.
SUBSTANCE: invention relates to use of diaminopyrimidine compound of formula I or IB, or its pharmaceutically acceptable salt, or its deuterated form. Invention also relates to versions of method of producing compound I. In compound of formula I
, 
, 
(Ia), 
(IIa),
R1 and R2 independently represent unsubstituted C1-8alkyl; C1-8alkyl substituted with one or more halogen atoms, hydroxy, C1-3alkoxy, C1-3alkoxyC1-3alkyl, halogen C1-3alkoxy or hydroxyC1-3alkyl; unsubstituted saturated 3–7-membered monocycloalkyl or 5–8-member bicycloalkyl; substituted saturated 3–7-member monocycloalkyl or 5–8-member bicycloalkyl, where substitutes are selected from halogen, C1-6 alkyl, hydroxy, oxo, C1-3alkoxy, C1-3alkoxyC1-3alkyl, halogen C1-3alkyl, halogen C1-3alkoxy, hydroxyC1-3alkyl, aminoC1-3alkyl, O-cyclopropyl, NH2, NH(C1-3) alkyl, N(C1-3alkyl)2, C(O)-C1-3alkyl, NHC(O)-C1-3alkyl, C(O)NH2, C(O)NHC1-3alkyl, C(O)N(C1-3alkyl)2, NHSO2(C1-3alkyl) and pyrrolidyl; unsubstituted C1-3alkyl-C3-6cycloalkyl; 4–6-member non-aromatic monocyclic heterocyclyl, optionally N-substituted with C1-3alkyl C(O) or optionally substituted C1-3alkyl, oxo or hydroxy, in which the heteroatoms are selected from 1 to 2 oxygen atoms or 1 nitrogen atom; or dioxaspirotecanil. In a compound of formula (IB) R3 and R4 independently represent unsubstituted C1-8alkyl; unsubstituted saturated 3–7-membered monocycloalkyl or 5–8-member bicycloalkyl; substituted saturated 3–7-member monocycloalkyl or 5–8-member bicycloalkyl, where substitutes are selected from halogen, C1-6alkyl, hydroxy, C1-3alkoxy, C1-3alkoxyC1-3alkyl, halogen C1-3alkyl, halogen C1-3alkoxy, hydroxyC1-3alkyl, O-cyclopropyl, NH(C1-3)alkyl, N(C1-3alkyl)2, C(O)-C1-3alkyl, NHC(O)-C1-3alkyl, C(O)NHC1-3alkyl and C(O)N(C1-3alkyl)2; unsubstituted C1-3alkyl-C3-6cycloalkyl; 4–6-member non-aromatic monocyclic heterocyclyl, in which heteroatoms are selected from 1–2 oxygen atoms or 1 nitrogen atom; or dioxaspirotecanil. Method of producing compound (I) involves reacting compound (Ia) with R1NH2 or compound (IIb) with R2NH2. Methods are carried out in a solvent in the presence of an organic base.
EFFECT: compounds have the properties of inhibitor JNK1, JNK2, IL2 or TNF-α and are intended for preparing a drug for treating or preventing non-alcoholic steatohepatitis, renal fibrosis, inflammation, hyperplasia, necrosis or lupus.
55 cl, 3 tbl, 62 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED DIAMINO-CARBOXAMIDE AND DIAMINO-CARBONITRILE PYRIMIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF TREATMENT USING THEM | 2012 |
|
RU2625309C2 |
| QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING SAME | 2011 |
|
RU2582610C2 |
| PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2661896C2 |
| N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2669922C2 |
| SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
| DIPEPTIDYL PEPTIDASE-IV INHIBITORS | 2010 |
|
RU2574410C2 |
| 6-[4-(1H-IMIDAZOL-2-YL)PIPERIDIN-1-YL]PYRIMIDIN-4-AMINE DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | 2014 |
|
RU2674261C2 |
| IMIDAZOPYRROLOPYRAZINE DERIVATIVES, USEFUL FOR TREATMENT OF DISEASES, CAUSED BY ABNORMAL ACTIVITY OF PROTEINKINASES Jak1, Jak3 OR Syk | 2010 |
|
RU2570416C2 |
| IMIDAZOPYRROLOPYRINE DERIVATIVES USEFUL FOR TREATING DISEASES CAUSED BY ABNORMAL ACTIVITY OF PROTEIN KINASES JAK1, JAK3 OR SYK | 2010 |
|
RU2711869C2 |
| COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
